The study shows that dasatinib, a Food and Drug Administration (FDA)-approved inhibitor of c-Kit, Proto-oncogene tyrosine-protein kinase (ABL, SRC) and Abelson murine leukemia viral oncogene homolog, may be potentially used in DDR2-positive SCC patients to block tumor cell invasion and migration [134]. This evidence concerns the gene KIT and neoplasm.